Solid Tumors trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Solid Tumors. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month46 studies across 30 companies, in the next 180 days.
August 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid TumorsNCT05262400Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle | Phase 1/2 | Active, not recruiting | 2026-08-23 | in 3 d | 2024-11-18 |
| CLRB | Cellectar Biosciences, Inc. | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasNCT03478462Number of participants with dose limiting toxicities (DLT) | Phase 1 | Active, not recruiting | 2026-08-25 | in 5 d | 2026-03-18 |
| ABBV | AbbVie | A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsNCT02099058Number of Participants with Adverse Events | Phase 1 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2025-08-14 |
September 2026 8
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsNCT06730750Number of participnats with Adverse Events (AEs) | Phase 1/2 | Recruiting | 2026-09-05 | in 16 d | 2026-07-02 |
| IBAB.BR | Ion Beam Applications | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)NCT07137195Short term efficacy evaluation | Not applicable | Active, not recruiting | 2026-09-05 | in 16 d | 2026-02-27 |
| ABBV | AbbVie | A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsNCT02988960Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 | Phase 1 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-01-09 |
| BMY | Bristol-Myers Squibb | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsNCT05888831Number of participants with Dose-Limiting Toxicities (DLTs) | Phase 1/2 | Active, not recruiting | 2026-09-30 | in 41 d | 2025-06-11 |
| CHRS | Coherus Oncology, Inc. | Study of CHS-114 in Participants With Advanced Solid TumorsNCT05635643[Arms 1a, 1b, and 2] Rate of Dose Limiting Toxicity (DLT) | Phase 1 | Active, not recruiting | 2026-09-30 | in 41 d | 2026-08-12 |
| ORIC | ORIC Pharmaceuticals | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationNCT05315700Recommended Phase 2 Dose (RP2D) | Phase 1/2 | Recruiting | Sep 2026 | ≤ 41 d | 2025-08-05 |
| TNGX | Tango Therapeutics, Inc. | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsNCT05887492Determine the MTD and RP2D(s) (Phase 1 only) | Phase 1/2 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-07-06 |
| TYRA | Tyra Biosciences, Inc | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene AlterationsNCT06160752Phase 1 Part A: To determine the maximum tolerated dose (MTD) of TYRA-200. | Phase 1 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-08-05 |
October 2026 8
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| 4568.T | Daiichi Sankyo | First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsNCT05875168Number of Participants with Dose-limiting Toxicities Following Treatment With DS-3939a | Phase 1/2 | Recruiting | 2026-10-20 | in 61 d | 2026-08-12 |
| ADAG | Adagene Inc | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsNCT05405595Maximum tolerated dose (MTD) and RP2D for ADG126 in combination with pembrolizumab. | Phase 1/2 | Recruiting | 2026-10-31 | in 72 d | 2026-01-07 |
| GILD | Gilead Sciences | Study of Sacituzumab Govitecan in Patients With Solid TumorNCT05119907Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Investigator Assessment | Phase 2 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2025-11-17 |
| GILD | Gilead Sciences | Study of GS-4528 in Adults With Solid TumorsNCT05840224Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-07-27 |
| IBAB.BR | Ion Beam Applications | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan)NCT07152353Short term efficacy evaluation | Not applicable | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-01-07 |
| IBAB.BR | Ion Beam Applications | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)NCT07153094Short term efficacy evaluation | Not applicable | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-01-16 |
| IDYA | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-07-13 |
| IMCR | Immunocore Ltd | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsNCT04262466Phase 1: Incidence of dose-limiting toxicity (DLT)s | Phase 1/2 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-03-06 |
November 2026 7
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Inc. | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.NCT06603844Occurance of Dose-limiting toxicities | Phase 1/2 | Recruiting | 2026-11-01 | in 73 d | 2025-06-03 |
| ERAS | Erasca, Inc. | A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsNCT04866134Evaluate safety and tolerability of escalating doses of ERAS-007 BID-QW | Phase 1/2 | Active, not recruiting | 2026-11-01 | in 73 d | 2026-06-22 |
| REGN | Regeneron Pharmaceuticals | A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersNCT04626635The incidence of Dose-Limiting Toxicities (DLTs) during the DLT period | Phase 1/2 | Active, not recruiting | 2026-11-13 | in 85 d | 2026-07-02 |
| EXEL | Exelixis | Study of XB010 in Subjects With Solid TumorsNCT06545331Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010 | Phase 1 | Recruiting | 2026-11-23 | in 95 d | 2026-06-22 |
| MGNX | MacroGenics | A Study of MGC028 in Participants With Advanced Solid TumorsNCT06723236Number and Types of Adverse Events (AEs) in Participants Receiving MGC028 | Phase 1 | Recruiting | Nov 2026 | ≤ 102 d | 2026-04-27 |
| REPL | Replimune, Inc. | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursNCT04735978Incidence of dose limiting toxicities (DLTs) during the DLT period | Phase 1 | Active, not recruiting | 2026-11-30 | in 102 d | 2026-02-27 |
| TYRA | Tyra Biosciences, Inc | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsNCT05544552Phase 1 Part A: To determine the maximum tolerated doses (MTD). | Phase 1/2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-01-12 |
December 2026 11
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AMGN | Amgen | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)NCT04185883Number of Participants with Dose Limiting Toxicities (DLTs) | Phase 1 | Active, not recruiting | 2026-12-17 | in 119 d | 2025-10-22 |
| AZN | AstraZeneca | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 | Phase 1 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-07-07 |
| GILD | Gilead Sciences | Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentNCT04617522Percentage of Participants experiencing Treatment Emergent Adverse Events (TEAEs) and Serious AEs | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-06-02 |
| GILD | Gilead Sciences | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid TumorsNCT06082960Percentage of Participants With Treatment-emergent Adverse Events | Phase 1 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-04-16 |
| MNPR | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-05-21 |
| NXTC | NextCure, Inc. | A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963Evaluate the safety and tolerability of LNCB74 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-12-16 |
| ONC | BeOne Medicines | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid TumorsNCT06625593Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2026-07-09 |
| ORIC | ORIC Pharmaceuticals | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCNCT06816992Recommended Phase 2 Dose (RP2D) | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-04-24 |
| PFE | Pfizer | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingNCT05059522Number of participants with adverse events leading to permanent discontinuation of study intervention | Phase 3 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-06-22 |
| PHIL.MI | Philogen S.p.A. | Safety and Early Signs of Efficacy of IL12-L19L19.NCT04471987For Part I: DLT | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-01-14 |
| RVMD | Revolution Medicines, Inc. | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541Adverse events | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2026-06-03 |
January 2027 9
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| INCY | Incyte Corporation | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06179160Number of participants with Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | 2027-01-01 | in 134 d | 2026-07-22 |
| REGN | Regeneron Pharmaceuticals | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With CemiplimabNCT05259709Incidence and severity of treatment-emergent adverse events (TEAEs) | Phase 1 | Recruiting | 2027-01-06 | in 139 d | 2025-09-11 |
| IDYA | IDEAYA Biosciences | Study of IDE397 in Participants With Solid Tumors Harboring MTAP DeletionNCT04794699Dose-limiting Toxicities (DLTs) of IDE397 | Phase 1 | Active, not recruiting | 2027-01-07 | in 140 d | 2026-04-09 |
| CRBP | Corbus Pharmaceuticals Inc. | A Phase 1/2 Study to Investigate CRB-701 in Solid TumorsNCT06265727Part A: To confirm the safety and tolerability and determine MTD and PADR for CRB-701 | Phase 1/2 | Recruiting | 2027-01-16 | in 149 d | 2026-01-08 |
| BMY | Bristol-Myers Squibb | A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid TumorsNCT07077434Maximum Plasma Concentration (Cmax) of BMS-986504 | Phase 1 | Recruiting | 2027-01-19 | in 152 d | 2026-06-03 |
| SNY | Sanofi | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsNCT05584670Dose escalation part 1A, 1C and Japan Cohort F: Presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2 | Phase 1/2 | Recruiting | 2027-01-19 | in 152 d | 2026-06-23 |
| IDYA | IDEAYA Biosciences | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsNCT03947385Dose-limiting Toxicity (DLT) | Phase 1/2 | Recruiting | 2027-01-29 | in 162 d | 2026-06-08 |
| EXEL | Exelixis | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | 2027-01-31 | in 164 d | 2026-08-05 |
| NUVL | Nuvalent Inc. | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)NCT06521554Recommended Phase 2 Dose (RP2D) | Phase 1 | Recruiting | Jan 2027 | ≤ 164 d | 2026-02-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Solid Tumors
most recently updated first838 studies match. Showing the first 100 of 838 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines | $545.6B | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent | Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer | 399 | 2023-12-01 | Nov 2028 | ≤ 833 d | 2026-08-19 |
| GILD | Gilead Sciences | $177.9B | Study of GS-5319 Given Alone or in Combination in Adults With Solid TumorsNCT07128303Percentage of Participants With Adverse Events (AEs) and Serous Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: GS-5319, Carboplatin, Pemetrexed, Pembrolizumab | Advanced Solid Tumor | 476 | 2025-08-28 | May 2028 | ≤ 650 d | 2026-08-19 |
| ONC | BeOne Medicines | $545.6B | A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsNCT07226349Phase 1a: Number of Participants with Adverse Events (AEs) | Phase 1 | Recruiting | Drug: BG-75098, BGB-43395, Fulvestrant | Advanced Solid Tumor | 105 | 2025-12-11 | 2028-11-01 | in 804 d | 2026-08-19 |
| AZN | AstraZeneca | — | Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid TumoursNCT00750841To assess the steady-state PK parameters of cediranib in the presence and absence of rifampicin | Phase 1 | Active, not recruiting | Drug: cediranib | Solid Tumors | 64 | 2008-09-09 | 2009-07-30actual | — | 2026-08-17 |
| APRE | Aprea Therapeutics | $8M | Study of APR-1051 in Patients With Advanced Solid TumorsNCT06260514Treatment-related adverse events | Phase 1 | Recruiting | Drug: APR-1051 | Advanced Solid Tumor | 90 | 2024-06-13 | Jun 2027 | ≤ 314 d | 2026-08-17 |
| 000100.KS | Yuhan Corporation | $4.2B | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946NCT06616766Treatment Emergent Adverse Events(TEAE)s | Phase 1/2 | Recruiting | Drug: YH42946 | NSCLC (Non-small Cell Lung Cancer), Solid Tumor | 201 | 2024-10-02 | 2028-03-15 | in 573 d | 2026-08-17 |
| NXTC | NextCure, Inc. | $30M | A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552dose escalation: Dose-limiting toxicity (DLT) | Phase 1 | Recruiting | Drug: SIM0505 for injection, SIM0505 for injection | Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (Prcc), Uterine Serous Carcinoma (USC), NSCLC (Non-small Cell Lung Cancer), Primary Peritoneal Cancer | 738 | 2025-02-26 | Feb 2028 | ≤ 558 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: PF-07799544, PF-07799933 | Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer) | 124 | 2022-11-30 | 2027-08-02 | in 347 d | 2026-08-14 |
| ONC | BeOne Medicines | $545.6B | An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid TumorsNCT07222267Part 1: Number of Participants with Adverse Events (AEs) | Phase 1 | Recruiting | Drug: BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor | Breast Cancer, Advanced Solid Tumor | 86 | 2025-12-11 | 2029-09-30 | in 1,137 d | 2026-08-14 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsNCT05407675results2025-10-03Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1/2 | Completed | Drug: BMS-986408, Rabeprazole · Biological: Nivolumab, Ipilimumab, Platinum-doublet chemotherapy | Advanced Solid Tumors | 68 | 2022-08-02 | 2024-08-22actual | — | 2026-08-13 |
| NXTC | NextCure, Inc. | $30M | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNCT05572684results2026-08-13Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Terminatedsponsor's stated reason: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Drug: NC410, pembrolizumab | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 97 | 2022-10-06 | 2025-04-30actual | — | 2026-08-13 |
| GILD | Gilead Sciences | $177.9B | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid TumorsNCT06167317The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation | Phase 1 | Recruiting | Drug: GS-0201, Sacituzumab Govitecan | Advanced Solid Tumors | 278 | 2024-01-09 | Sep 2028 | ≤ 772 d | 2026-08-13 |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsNCT07066657Dose Limiting Toxicity (DLT) - Phase Ia | Phase 1 | Recruiting | Drug: MRG007, MRG007 and Bevacizumab | Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer | 572 | 2025-07-25 | Mar 2028 | ≤ 589 d | 2026-08-13 |
| AZN | AstraZeneca | — | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesNCT05417594Incidence of Adverse Events (AEs), and Serious Adverse Events (SAEs) | Phase 1/2 | Recruiting | Drug: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd) | Advanced Solid Malignancies | 695 | 2022-06-24 | 2028-02-07 | in 536 d | 2026-08-12 |
| CHRS | Coherus Oncology, Inc. | $207M | Study of CHS-114 in Participants With Advanced Solid TumorsNCT05635643[Arms 1a, 1b, and 2] Rate of Dose Limiting Toxicity (DLT) | Phase 1 | Active, not recruiting | Drug: CHS-114, toripalimab | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | 87 | 2022-12-15 | 2026-09-30 | in 41 d | 2026-08-12 |
| 4568.T | Daiichi Sankyo | $31.7B | First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsNCT05875168Number of Participants with Dose-limiting Toxicities Following Treatment With DS-3939a | Phase 1/2 | Recruiting | Drug: DS-3939a | Advanced Solid Tumor, Metastatic Solid Tumor | 590 | 2023-08-18 | 2026-10-20 | in 61 d | 2026-08-12 |
| RADX | Radiopharm Theranostics, Ltd | — | Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain MetastasesNCT06777433Concordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium | Phase 2 | Active, not recruiting | Drug: RAD101 (18F-FPIA) | Brain Metastases From Solid Tumors | 30 | 2024-12-13 | 2026-04-23actual | — | 2026-08-12 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.NCT07372625Metformin Cmax geometric mean ratio | Phase 1 | Recruiting | Drug: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt | TP53 Y220C Mutation, Advanced Solid Tumors | 14 | 2026-02-04 | Mar 2027 | ≤ 223 d | 2026-08-12 |
| AZN | AstraZeneca | — | A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursNCT05514132The number of subjects with dose-limiting toxicity, as defined in the protocol. | Phase 1 | Active, not recruiting | Drug: Ceralasertib, Durvalumab | Advanced Solid Tumours | 14 | 2022-09-23 | 2023-10-20actual | — | 2026-08-11 |
| AMGN | Amgen | $229.9B | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsNCT06131398Number of Participants Who Experience a Dose Limiting Toxicity (DLT) | Phase 1 | Completed | Drug: AMG 355, Pembrolizumab | Advanced Solid Tumors | 77 | 2024-03-07 | 2026-07-22actual | — | 2026-08-11 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid TumorsNCT07160725Number of Participants with Adverse Events (AE) | Phase 1/2 | Recruiting | Drug: BMS-986517, Pumitamig | Solid Tumours | 540 | 2025-10-15 | 2028-07-31 | in 711 d | 2026-08-11 |
| AZN | AstraZeneca | — | Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid TumoursNCT07446855Parts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs) | Phase 1/2 | Recruiting | Drug: AZD4956, Saruparib | Solid Tumours | 180 | 2026-03-17 | 2030-03-29 | in 1,317 d | 2026-08-11 |
| RIGL | Rigel Pharmaceuticals | $815M | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesNCT07486713Area Under the Plasma Concentration-Time Curve (AUC) of Probe Drugs | Phase 4 | Recruiting | Drug: Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies | 16 | 2026-02-23 | 2027-04-30 | in 253 d | 2026-08-11 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2020-10-29 | 2026-08-15 | — | 2026-08-10 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| ONC | BeOne Medicines | $545.6B | A Study of BGB-B455 in Adults With Advanced or Metastatic Solid TumorsNCT06803680Phase 1a: Number of participants with adverse events (AEs) and serious adverse events (SAEs) | Phase 1 | Recruiting | Drug: BGB-B455, Chemotherapy | Advanced Solid Tumor, Metastatic Solid Tumor | 90 | 2025-03-18 | 2028-04-29 | in 618 d | 2026-08-10 |
| IMNM | Immunome, Inc. | $3.1B | A Phase 1 Study of IM-1021 in Participants With Advanced CancerNCT06823167Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs) | Phase 1 | Recruiting | Drug: IM-1021 | Solid Malignancies, Hematologic Malignancies | 190 | 2025-02-26 | May 2028 | ≤ 650 d | 2026-08-10 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsNCT06880549Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Biological: mRNA-4106, Pembrolizumab, mRNA-4200 | Advanced Solid Tumors | 42 | 2025-03-25 | 2027-08-03 | in 348 d | 2026-08-10 |
| AZN | AstraZeneca | — | A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care TherapyNCT07161414Area under the Concentration-time Curve During One Dosing Interval (AUCtau) | Phase 1 | Recruiting | Drug: IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig, SC rilvegostomig + rHu | Advanced Solid Tumors | 40 | 2025-11-25 | 2027-07-19 | in 333 d | 2026-08-10 |
| 4568.T | Daiichi Sankyo | $31.7B | First-in-Human Trial of DS1025a in Participants With Advanced Solid TumorsNCT07681882Number of Participants Reporting Dose-limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: DS1025a | Advanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid Tumor | 45 | 2026-08-06 | 2028-01-21 | in 519 d | 2026-08-10 |
| GILD | Gilead Sciences | $177.9B | A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid TumorsNCT07703878Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: GS-1206 | Solid Tumor | 302 | 2026-07-17 | Sep 2029 | ≤ 1,137 d | 2026-08-10 |
| RIGL | Rigel Pharmaceuticals | $815M | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsNCT07704658Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf) | Phase 4 | Recruiting | Drug: Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive | NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies | 12 | 2026-03-04 | 2027-07-30 | in 344 d | 2026-08-10 |
| TEM | Tempus AI | $8.6B | Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in CancerNCT07756034observationalCompleteness and Yield of Multi-Modal Real-World Data Capture | — | Recruiting | — | Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia, Hematologic Malignancies | 1,000 | Aug 2026 | Jul 2031 | ≤ 1,806 d | 2026-08-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationNCT04280081results2022-06-02Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC) | Phase 2 | Active, not recruiting | Drug: Selpercatinib | Solid Tumor, Medullary Thyroid Cancer | 77 | 2020-03-16 | 2021-03-25actual | — | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) | Phase 1 | Recruiting | Drug: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel | Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor | 340 | 2024-09-19 | Oct 2027 | ≤ 437 d | 2026-08-07 |
| ONC | BeOne Medicines | $545.6B | Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid TumorsNCT06598800Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: Drug: BG-T187, Other Therapeutic Agents | Advanced Solid Tumor | 153 | 2024-10-18 | 2028-09-30 | in 772 d | 2026-08-07 |
| AZN | AstraZeneca | — | Phase I Comparative Bioavailability StudyNCT00777582PK Phase Primary Outcome: To determine the comparative bioavailability of a new tablet formulation of AZD2281 compared to the existing capsule formulation | Phase 1 | Active, not recruiting | Drug: AZD2281 | Solid Tumors | 197 | 2008-10-27 | 2009-02-06actual | — | 2026-08-06 |
| NVCT | Nuvectis Pharma, Inc. | $681M | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNCT05226507Part A: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicities | Phase 1 | Terminatedsponsor's stated reason: Study terminated due to various reasons impacting the feasibility of future clinical development | Drug: NXP800 | Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation | 45 | 2021-12-31 | 2025-01-01actual | — | 2026-08-06 |
| AZN | AstraZeneca | — | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours | Phase 1 | Recruiting | Biological: NT-175 | Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS) | 45 | 2023-07-12 | 2029-07-31 | in 1,076 d | 2026-08-06 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesNCT07195916Part 1A : Occurrence of Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: INCA036873 | Solid Tumors, Hematologic Malignancies | 280 | 2026-01-08 | 2028-08-18 | in 729 d | 2026-08-06 |
| ONC | BeOne Medicines | $545.6B | A First-in-Human Study of BG-C0979 in Adults With Advanced Solid TumorsNCT07414836Phase 1a: Number of Participants Experiencing Adverse Events (AEs) | Phase 1 | Recruiting | Drug: BG-C0979, Tislelizumab | Advanced Solid Tumor | 84 | 2026-04-13 | 2029-04-30 | in 984 d | 2026-08-06 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaNCT07522073Overall Survival (OS) | Phase 3 | Recruiting | Drug: INCB161734, Placebo, Investigator's choice of chemotherapy | Solid Tumors | 588 | 2026-04-09 | 2028-09-15 | in 757 d | 2026-08-06 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | A Study of IOV-5001 in Adults With Advanced Solid TumorsNCT07743723Phase 1: Safety Assessment | Phase 1/2 | Not yet recruiting | Biological: IOV-5001 | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor | 106 | Aug 2026 | Mar 2034 | ≤ 2,780 d | 2026-08-06 |
| ARVN | Arvinas Inc. | $605M | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsNCT07749586Part A1: Number of Dose-Limiting Toxicities (DLTs) of ARV-6723 | Phase 1/2 | Recruiting | Drug: ARV-6723, Pembrolizumab, SOC | Advanced Solid Tumor | 499 | 2026-07-29 | 2031-03-31 | in 1,684 d | 2026-08-06 |
| EXEL | Exelixis | $13.2B | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Including Immune-Mediated Adverse Events (imAEs) | Phase 1 | Recruiting | Drug: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI) | 1,394 | 2021-12-14 | 2027-01-31 | in 164 d | 2026-08-05 |
| TYRA | Tyra Biosciences, Inc | $1.6B | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene AlterationsNCT06160752Phase 1 Part A: To determine the maximum tolerated dose (MTD) of TYRA-200. | Phase 1 | Active, not recruiting | Drug: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles | Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma | 40 | 2023-11-22 | Sep 2026 | ≤ 41 d | 2026-08-05 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)NCT06330064Objective Response Rate (ORR) as Assessed by Investigator | Phase 1/2 | Recruiting | Drug: Ifinatamab deruxtecan | Recurrent or Metastatic Solid Tumors | 680 | 2024-04-10 | 2028-07-25 | in 705 d | 2026-08-05 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| APRE | Aprea Therapeutics | $8M | Study Of ATRN-119 In Patients With Advanced Solid TumorsNCT04905914Treatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statistics | Phase 1/2 | Completed | Drug: ATRN-119 | Advanced Solid Tumor | 43 | 2023-01-09 | 2026-03-09actual | — | 2026-08-04 |
| NTRA | Natera, Inc. | $44.9B | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NCT07689812To demonstrate that ctDNA-guided intermittent ICI therapy results in at least 50% of patients who do not reinitiate systemic therapy prior to 6 months from randomization. | Not applicable | Not yet recruiting | Device: Signatera Genome ultra-sensitive ctDNA blood test | NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC, Melanoma (Skin Cancer), Melanoma (Skin) Stage IV, CRC, MSI High Colorectal Cancer, DMMR Colorectal Cancer, RCC, Renal Cell Cancer, RCC, Solid Tumors, Metastatic Solid Tumors, Advanced Solid Tumors, Advanced Solid Tumors Cancer | 920 | Dec 2026 | Dec 2033 | ≤ 2,690 d | 2026-08-04 |
| ONC | BeOne Medicines | $545.6B | A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) MutationsNCT07746141Phase 1a (Part A and Part B): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Not yet recruiting | Drug: BG-85738, Tislelizumab, Cetuximab | RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor | 100 | 2026-09-04 | 2028-09-30 | in 772 d | 2026-08-04 |
| PLRX | Pliant Therapeutics, Inc. | $71M | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsNCT06270706Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2 | Phase 1 | Recruiting | Drug: PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095, Pembrolizumab | Advanced or Metastatic Solid Tumor | 124 | 2023-08-30 | Jun 2030 | ≤ 1,410 d | 2026-08-03 |
| ONC | BeOne Medicines | $545.6B | A Study of BG-C477 in Participants With Advanced Solid TumorsNCT06596473Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: BG-C477, Tislelizumab, Chemotherapy | Advanced Solid Tumors | 310 | 2024-10-03 | 2027-12-31 | in 498 d | 2026-08-03 |
| RVMD | Revolution Medicines, Inc. | $46.3B | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsNCT07397338Number of patients with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only), cetuximab (Cohort C2 Only), Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only), Daraxonrasib (Cohort B1 only) | Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC | 370 | 2026-01-30 | May 2029 | ≤ 1,015 d | 2026-08-03 |
| GILD | Gilead Sciences | $177.9B | Study of GS-2426 in Participants With Advanced Solid TumorsNCT07601243Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAE) | Phase 1 | Recruiting | Drug: GS-2426 | Advanced Solid Tumors | 174 | 2026-06-02 | Jan 2029 | ≤ 895 d | 2026-08-03 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of ASP3082 in Adults With Advanced Solid TumorsNCT05382559Incidence of Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil, Irinotecan, Nanoparticle albumin-bound-paclitaxel, Gemcitabine, Docetaxel, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Liposomal Irinotecan | Solid Tumor | 681 | 2022-06-08 | 2028-12-31 | in 864 d | 2026-07-31 |
| ERAS | Erasca, Inc. | $6.3B | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid TumorsNCT06983743Dose Limiting Toxicities (DLT) | Phase 1 | Recruiting | Drug: ERAS-0015, ERAS-0015 in combination | Metastatic Solid Tumors | 600 | 2025-06-05 | 2028-05-01 | in 620 d | 2026-07-31 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of DS-3939a in Participants With Solid TumorsNCT07739966Part 1: Number of Participants With Dose-limiting Toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: DS-3939a, Pembrolizumab, Carboplatin, Pemetrexed, DS-1103a | Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | 400 | 2026-10-01 | 2030-07-31 | in 1,441 d | 2026-07-31 |
| 4519.T | Chugai Pharmaceutical | $72.4B | A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).NCT04511845Safety and tolerability of SPYK04 (Dose limiting toxicities) [Dose escalation] | Phase 1 | Completed | Drug: SPYK04 | Locally Advanced or Metastatic Solid Tumors | 85 | 2020-09-10 | 2026-06-18actual | — | 2026-07-30 |
| IPN.PA | Ipsen | $15.5B | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursNCT06305247Phase 1: Percentage of participants with dose limiting toxicity (DLT) | Phase 1/2 | Active, not recruiting | Drug: IPN01194, IPN01194 | Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor | 36 | 2024-04-03 | 2028-03-20 | in 578 d | 2026-07-30 |
| IPN.PA | Ipsen | $15.5B | A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid TumoursNCT06833008Part A: Percentage of participants with dose limiting toxicity (DLT) | Phase 1/2 | Recruiting | Drug: IPN01195 | Advanced Solid Tumor | 85 | 2025-03-14 | 2028-10-03 | in 775 d | 2026-07-30 |
| AZN | AstraZeneca | — | Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of SaruparibNCT06899061Module 1: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf) of digoxin, furosemide, metformin and rosuvastatin when dosed alone and in combination with saruparib | Phase 1 | Active, not recruiting | Drug: Saruparib, Digoxin, Furosemide, Metformin Hydrochloride, Rosuvastatin, Rabeprazole | Advanced Solid Malignancies | 41 | 2025-03-25 | 2026-02-03actual | — | 2026-07-30 |
| IPN.PA | Ipsen | $15.5B | A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid TumoursNCT07213817Phase Ia: Percentage of participants with dose limiting toxicity (DLT) | Phase 1/2 | Recruiting | Biological: IPN60300 | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 114 | 2025-12-05 | 2028-10-30 | in 802 d | 2026-07-30 |
| IPN.PA | Ipsen | $15.5B | A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor TherapiesNCT07213830Percentage of participants with dose limiting toxicity (DLT) | Phase 1/2 | Recruiting | Biological: IPN01203 | Advanced Solid Tumor, Metastatic Solid Tumor | 102 | 2026-02-06 | 2032-07-14 | in 2,155 d | 2026-07-30 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680Part 1: Number of participants who achieve Objective Response (OR) | Phase 2 | Recruiting | Drug: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel | Solid Tumors | 260 | 2026-07-27 | 2028-08-15 | in 726 d | 2026-07-30 |
| INBX | Inhibrx Biosciences, Inc | $1.4B | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab | Phase 1/2 | Recruiting | Drug: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer | 340 | 2019-12-10 | Jul 2033 | ≤ 2,537 d | 2026-07-29 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsNCT05536141Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: casdatifan, Cabozantinib, Zimberelimab, Ipilimumab | Clear Cell Renal Cell Carcinoma, Solid Tumors | 362 | 2022-10-26 | Mar 2029 | ≤ 954 d | 2026-07-29 |
| TYRA | Tyra Biosciences, Inc | $1.6B | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway AberrationsNCT06915753Maximum tolerated dose (MTD) | Phase 1 | Recruiting | Drug: TYRA-430 | Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, FGFR3 Gene Fusions, Locally Advanced Unresectable Hepatocellular Carcinoma | 100 | 2025-04-24 | Jan 2028 | ≤ 529 d | 2026-07-29 |
| AZN | AstraZeneca | — | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)NCT07044336Progression Free Survival (PFS) for Arm A vs Arm B | Phase 3 | Recruiting | Drug: Puxitatug Samrotecan, Doxorubicin, Paclitaxel | Endometrial Cancer, Malignant Solid Tumour | 800 | 2025-08-01 | 2027-10-15 | in 421 d | 2026-07-29 |
| IMNM | Immunome, Inc. | $3.1B | A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced CancerNCT07505771Safety and tolerability of 177Lu-IM-3050 in participants with advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs) | Early Phase 1 | Recruiting | Drug: 177Lu-IM-3050 | Solid Malignancies | 105 | 2026-06-19 | Dec 2029 | ≤ 1,229 d | 2026-07-29 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of DS-1103a Combination Therapy in Participants With Advanced Solid TumorsNCT05765851Number of Participants with Dose-limiting Toxicities (Dose Escalation) | Phase 1 | Recruiting | Drug: DS-1103a, T-DXd | Advanced Solid Tumor | 108 | 2023-05-30 | 2030-05-15 | in 1,364 d | 2026-07-28 |
| 4519.T | Chugai Pharmaceutical | $72.4B | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid TumorsNCT05907980The maximum tolerated dose (MTD) and the recommended dose (RD) of ROSE12 when administered as a single agent and in combination with atezolizumab (Part A and C) | Phase 1 | Recruiting | Drug: ROSE12, Atezolizumab, Pembrolizumab | Solid Tumor | 209 | 2023-05-24 | 2027-10-31 | in 437 d | 2026-07-28 |
| AZN | AstraZeneca | — | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsNCT06218914Part A (Dose Escalation): Evaluate the safety of KRAS TCRTs in subjects with unresectable, advanced, and/or metastatic solid tumors | Phase 1 | Recruiting | Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D | Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D | 108 | 2024-03-22 | 2027-08-30 | in 375 d | 2026-07-28 |
| GILD | Gilead Sciences | $177.9B | Study of GS-4528 in Adults With Solid TumorsNCT05840224Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Biological: GS-4528 · Drug: Zimberelimab | Solid Tumor | 182 | 2023-05-11 | Oct 2026 | ≤ 72 d | 2026-07-27 |
| IPH.PA | Innate Pharma | $170M | Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsNCT06781983Safety and Tolerability | Phase 1 | Active, not recruiting | Drug: IPH4502 | Advanced or Metastatic Solid Tumors | 145 | 2025-01-24 | Apr 2028 | ≤ 619 d | 2026-07-27 |
| AZN | AstraZeneca | — | A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug ZNCT06929260Area under plasma concentration-time curve from time 0 to infinity (AUCinf) | Phase 1 | Terminatedsponsor's stated reason: The study terminated because the clinical development programme for Ceralasertib has been discontinued. | Drug: Ceralasertib, Drug X, Drug Y, Drug Z | Advanced Solid Tumours | 1 | 2025-05-21 | 2025-10-15actual | — | 2026-07-24 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsNCT05836324Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: INCA33890, bevacizumab, FOLFIRI, FOLFOX, Cetuximab, ADG126 | Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors | 570 | 2023-07-24 | 2029-05-03 | in 987 d | 2026-07-23 |
| AMGN | Amgen | $229.9B | A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationNCT07172919Number of Participants with Treatment-Emergent Adverse Events (TEAEs) | Phase 2 | Recruiting | Drug: Sotorasib, Panitumumab | Advanced Solid Tumors | 14 | 2026-01-02 | 2028-07-01 | in 681 d | 2026-07-23 |
| LLY | Eli Lilly and Company | $1.15T | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsNCT04521686Recommended Phase 2 Dose (RP2D) | Phase 1 | Active, not recruiting | Drug: LY3410738, Gemcitabine, Cisplatin, Durvalumab | Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor | 200 | 2020-10-01 | 2023-07-17actual | — | 2026-07-22 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06179160Number of participants with Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX, FOLFOX, FOLFIRI, INCA33890 | Solid Tumors | 710 | 2024-01-04 | 2027-01-01 | in 134 d | 2026-07-22 |
| ONC | BeOne Medicines | $545.6B | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid TumorsNCT06589596Phase 1a: Number of Participants with Adverse Events and Serious Adverse Events | Phase 1 | Recruiting | Drug: BGB-58067, BG-89894, Standard of Care Therapy | Advanced Solid Tumor | 525 | 2025-01-10 | 2027-09-30 | in 406 d | 2026-07-22 |
| BNTX | BioNTech SE | — | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsNCT07070232Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs) | Phase 1/2 | Recruiting | Drug: BNT326, Pumitamig, Itraconazole, Paroxetine | Advanced Solid Tumor | 1,438 | 2025-08-12 | Mar 2028 | ≤ 589 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation | Phase 1 | Recruiting | Drug: PF-08046876 | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer | 310 | 2025-08-20 | 2028-07-08 | in 688 d | 2026-07-22 |
| INCY | Incyte Corporation | $24.7B | Study of INCB123667 in Subjects With Advanced Solid TumorsNCT05238922Part 1A : Occurrence of Dose Limiting Toxicities (DLTs) | Phase 1 | Active, not recruiting | Drug: INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant | Solid Tumors | 291 | 2022-07-05 | 2027-07-27 | in 341 d | 2026-07-21 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid TumorsNCT06244485Number of Participants Reporting Dose-limiting Toxicities (Part 1 Dose Escalation) | Phase 1 | Active, not recruiting | Drug: Valemetostat tosylate, T-DXd, Dato-DXd | Advanced Solid Tumor | 98 | 2024-02-16 | 2028-11-01 | in 804 d | 2026-07-21 |
| AAPG | Ascentage Pharma Group Inc. | — | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STNCT06687070Treatment-related adverse events per NCI-CTCAE version 5.0. | Phase 1 | Recruiting | Drug: APG -2449, PLD | Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor | 90 | 2024-12-17 | May 2027 | ≤ 284 d | 2026-07-21 |
| LLY | Eli Lilly and Company | $1.15T | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsNCT06607185Number of Participants with Dose-limiting Toxicities (DLTs) | Phase 1 | Active, not recruiting | Drug: LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor | 750 | 2024-10-21 | Jan 2030 | ≤ 1,260 d | 2026-07-20 |
| 4519.T | Chugai Pharmaceutical | $72.4B | Study of AUBE00 in Patients With Solid TumorsNCT07030959Adverse events of AUBE00 [Part A, B, C] | Phase 1 | Recruiting | Drug: AUBE00, Cetuximab | Solid Tumors | 130 | 2025-06-05 | 2029-12-31 | in 1,229 d | 2026-07-20 |
| ACTU | Actuate Therapeutics Inc. | $25M | Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid TumorsNCT07714395To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and dose-limiting toxicities (DLTs) of elraglusib tablets | Phase 1/2 | Not yet recruiting | Drug: Elraglusib Oral Tablets | Advanced Malignant Solid Tumor | 100 | Oct 2026 | Jul 2029 | ≤ 1,076 d | 2026-07-20 |
| GILD | Gilead Sciences | $177.9B | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid MalignanciesNCT05006794Percentage of Patients Experiencing Dose-Limiting Toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to terminate | Drug: zamzetoclax, Docetaxel, sacituzumab govitecan-hziy | Solid Malignancies | 37 | 2021-09-15 | 2025-06-16actual | — | 2026-07-17 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study to Find a Suitable Dose of ASP4396 in Adults With Solid TumorsNCT06364696Incidence of Dose Limiting Toxicities (DLTs) for ASP4369 | Phase 1 | Terminatedsponsor's stated reason: Company's strategic decision | Drug: ASP4396 | Solid Tumor | 60 | 2024-04-16 | 2026-06-17actual | — | 2026-07-16 |
| CHRS | Coherus Oncology, Inc. | $207M | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid TumorsNCT04374877[Part A] Dose Limiting Toxicity (DLT) | Phase 1 | Completed | Drug: CHS-388, Pembrolizumab, Toripalimab | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | 145 | 2020-04-22 | 2025-05-28actual | — | 2026-07-15 |
| CTMX | CytomX Therapeutics | $739M | First In Human Study of CX-2051 in Advanced Solid TumorsNCT06265688Safety and tolerability of CX-2051 | Phase 1 | Recruiting | Drug: CX-2051, Bevacizumab | Solid Tumor, Adult | 160 | 2024-04-02 | 2027-11-30 | in 467 d | 2026-07-15 |
| CHRS | Coherus Oncology, Inc. | $207M | A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid TumorsNCT06657144Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin | Metastatic Solid Tumor, Advanced Solid Tumor | 154 | 2025-04-01 | Jan 2028 | ≤ 529 d | 2026-07-15 |
| MRNA | ModernaTX, Inc. | $25.1B | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsNCT05533697Arms 1a and 1b: Maximum Tolerated Dose (MTD) or Recommended Dose for Expansion (RDE) of mRNA-4359 | Phase 1/2 | Recruiting | Biological: mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab | Advanced Solid Tumors | 361 | 2022-09-01 | 2032-02-18 | in 2,008 d | 2026-07-14 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Drug: IDE-161, Pembrolizumab | Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC | 216 | 2023-04-18 | Oct 2026 | ≤ 72 d | 2026-07-13 |
| AZN | AstraZeneca | — | A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabNCT07391670Area under the concentration-time curve | Phase 1 | Recruiting | Drug: SC durvalumab + rHu, IV durvalumab, Tremelimumab | Solid Tumours | 40 | 2026-03-31 | 2027-08-30 | in 375 d | 2026-07-13 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsNCT05101096Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) Defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 | Phase 1/2 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy | Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer | 135 | 2021-10-20 | May 2027 | ≤ 284 d | 2026-07-10 |
| BMY | Bristol-Myers Squibb | $134.9B | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: BMS-986500, Palbociclib, Fulvestrant | Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer | 234 | 2025-08-01 | 2028-12-14 | in 847 d | 2026-07-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Solid Tumors is matched — 46 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Solid Tumors
- Advanced Solid Tumors
- Solid Tumor
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Solid Tumor, Adult
- Advanced Solid Malignancies
- Solid Tumours
- Advanced or Metastatic Solid Tumors
- Advanced Solid Tumours
- Metastatic Solid Tumors
- Advanced Solid Tumors Cancer
- Malignant Solid Tumor
- Unspecified Adult Solid Tumor, Protocol Specific
- Locally Advanced Solid Tumor
- Other Solid Tumors
- Advanced Malignant Solid Tumors
- Advanced/Metastatic Solid Tumors
- Solid Tumour
- Locally Advanced or Metastatic Solid Tumors
- Solid Malignancies
- Solid Tumors and Hematologic Malignancy
- Unresectable Solid Tumor
- Malignant Solid Tumour
- Solid Tumor Malignancies
- Advanced Malignant Solid Tumor
- EGFR Positive Solid Tumor
- Malignant Solid Tumors
- Refractory Solid Tumor
- Refractory Solid Tumors
- Select Advanced Solid Tumors
- Solid Tumor Cancer
- Solid Tumor Malignancy
- Solid Tumors, Adult
- Advanced Solid Malignancy
- Advanced Solid Tumor, Adult
- Advanced or Metastatic Solid Tumor
- Any Solid Tumor
- Brain Metastases From Solid Tumors
- Mismatch Repair Deficient or MSI-High Solid Tumors
- Pediatric Solid Tumor
- Recurrent Solid Tumor
- Recurrent or Metastatic Solid Tumors
- Relapsed Solid Tumor
- Solid Neoplasms
- Unspecified Childhood Solid Tumor, Protocol Specific
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Solid Tumors” (a text search, wider than this page)